The Vericiguat in Vasospastic Angina (ViVA) trial: a double-blind placebo-controlled randomized cross-over study

28 August 2026 (08:15 - 08:33)

Organised by:

Video

Slides

Sign in for access options

About the speaker

Miss Hanae Namba

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

4 More presentations in this session

Presentation thumbnail

Incremental diagnostic value of coronary microvascular dysfunction testing in patients with a working diagnosis of myocardial infarction with nonobstructive coronary arteries by stress CMR

Mrs J. Nickander (Stockholm, SE)

Presentation thumbnail

Microvascular Resistance Reserve and Cardiovascular Outcomes: Prespecified Analysis of FLOW-CMD

Associate Professor J. Lee (Seoul, KR)

Presentation thumbnail

The DiagnOsis of MINOCA (DOMINO) registry: a real-world use of multimodality imaging and its impact on etiologic classification

Associate Professor D. Morrone (Pisa, IT)

Presentation thumbnail

CMR-Derived Epicardial Adipose Tissue Differentiates Etiologies and Predicts Outcomes in Patients With Suspected MINOCA

Associate Professor W. Chen (Xuzhou, CN)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: management of coronary microvascular disease

The Event

Event poster

ESC Congress 2026

28 August 2026 08:15 CET

You may be interested in

Congress Session

Diagnosis and treatment of microvascular and epicardial coronary artery disease

30 August 2024

Congress Presentation

Spotlight on soluble guanylate cyclase stimulation

30 August 2026

Congress Presentation

Vericiguat as a novel therapeutic approach for refractory angina due to coronary spasm

29 August 2025

Congress Session

Latest science in pharmacotherapy

29 August 2022

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources